1 / 7

Visudyne Macular Edema Market Analysis Report to 2023

RnRMarketResearch.com adds “Visudyne (Macular Edema and Macular Degeneration) – Forecast and Market Analysis to 2023”to its store. Visudyne(Macular Edema and Macular Degeneration) – Forecast and Market Analysis to 2023.

Rudra1234
Download Presentation

Visudyne Macular Edema Market Analysis Report to 2023

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Visudyne (Macular Edema and Macular Degeneration) Forecast and Market Analysis to 2023 By RnRMarketResearch Browse more reports on Pharmaceuticals athttp://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  2. Visudyne (Macular Edema and Macular Degeneration) Forecast and Market Analysis to 2023 Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  3. Visudyne (Macular Edema and Macular Degeneration) Forecast and Market Analysis to 2023 Visudyne (verteporfin) is a photosensitizer molecule that was co-developed by QLT PhotoTherapeutics and Novartis Pharma AG for use in a two-step procedure involving the use of a non-thermal laser light, known as PDT. It was initially approved by the FDA in April 2000 for the treatment of patients with predominantly classical subfoveal CNV due to AMD. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Complete Report is available at http://www.rnrmarketresearch.com/visudyne-macular-edema-and-macular-degeneration-forecast-and-market-analysis-to-2023-market-report.html . ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  4. Visudyne (Macular Edema and Macular Degeneration) Forecast and Market Analysis to 2023 Scope: Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on Visudyne including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for Visudyne for the top seven countries from 2013 to 2023. Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  5. Visudyne (Macular Edema and Macular Degeneration) Forecast and Market Analysis to 2023 Reasons to Buy: • Understand and capitalize by identifying products that are most likely to ensure a robust return. • Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration. • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential. • Make more informed business decisions from insightful and in-depth analysis of Visudyne performance. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  6. Visudyne (Macular Edema and Macular Degeneration) Forecast and Market Analysis to 2023 Table of Contents: 1 Table of Contents 61.1 List of Tables 81.2 List of Figures 82 Introduction 92.1 Related Reports 103 Disease Overview 123.1 Macular Degeneration Overview 123.1.1 Etiology and Pathophysiology 143.1.2 Classification 183.1.3 Symptoms and Diagnosis 203.2 Macular Edema Overview 233.2.1 Etiology and Pathophysiology 243.2.2 Classification 27 ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  7. Visudyne (Macular Edema and Macular Degeneration) Forecast and Market Analysis to 2023 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

More Related